Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 4/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11836878 | 0.74 | CYP2C9 (0.50) | CYP2C9ALDH1A1BLMPMP22CACNA1F | |
| SCHEMBL7327872 | 0.73 | BACE1 (0.46) | CYP2C9ALDH1A1BLMPMP22CACNA1F | |
| SCHEMBL11929302 | 0.73 | ALDH1A1 (0.42) | CYP2C9ALDH1A1BLMPMP22CACNA1F | |
| SCHEMBL4782380 | 0.71 | CYP2C9 (0.47) | CYP2C9ALDH1A1BLMPMP22CACNA1F | |
| SCHEMBL11925190 | 0.69 | GAA (0.48) | CYP2C9ALDH1A1BLMPMP22CACNA1F | |
| SCHEMBL8665106 | 0.66 | ALDH1A1 (0.42) | CYP2C9ALDH1A1BLMPMP22CACNA1F | |
| Phenytoin SCHEMBL29415216 | 0.64 | CYP2C9 (0.49) | CYP2C9ALDH1A1BLMPMP22CACNA1F | |
| SCHEMBL9285876 | 0.63 | ALDH1A1 (0.45) | CYP2C9ALDH1A1BLMPMP22CACNA1F | |
| SCHEMBL11723745 | 0.63 | CYP2C9 (0.79) | CYP2C9ALDH1A1BLMPMP22CACNA1F | |
| SCHEMBL4727177 | 0.63 | ALDH1A1 (0.62) | CYP2C9ALDH1A1BLMPMP22CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891021-B1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-2644600-B1 | Heterocyclic aspartyl protease inhibitors | MERCK SHARP & DOHME (US) | 2017-01-11 | — | — | EP | disclosed |
| US-9382242-B2 | Preparation and use of compounds as protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140206715-A1 | PREPARATION AND USE OF COMPOUNDS AS PROTEASE INHIBITORS | PHARMACOPEIA, LLC | 2014-07-24 | — | — | US | disclosed |
| EP-2064191-B1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-1896478-B1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8722708-B2 | Substituted isoindolines as aspartyl protease inhibitors | Merck Sharp & Dohme Inc. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8629155-B2 | Aspartyl protease inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2644600-A1 | Heterocyclic aspartyl protease inhibitors | Merck Sharp & Dohme Corp. (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-2345411-B1 | Heterocyclic aspartyl protease inhibitors, preparation and use thereof | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2006138192-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138266-A2 | THE PREPARATION AND USE OF COMPOUNDS AS ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138217-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138230-A2 | THE PREPARATION AND USE OF PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138265-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS, PREPARATION AND USE THEREOF | SCHERING CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287294-A1 | Aspartyl protease inhibitors | MERCK SHARP & DOHME LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060281730-A1 | Aspartyl protease inhibitors | SCHERING CORPORATION | 2006-12-14 | — | — | US | disclosed |
| WO-2006009653-A1 | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050282825-A1 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | WYETH (US) | 2005-12-22 | — | — | US | disclosed |
| US-20050282825-A1 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | WYETH (US) | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287294-A1 | Aspartyl protease inhibitors | CHRM1, BACE1, CHRM2 | CYP2C9 2198/4885ALDH1A1 2461/4885BLM 3805/4885 |
| US-20140206715-A1 | PREPARATION AND USE OF COMPOUNDS AS PROTEASE INHIBITORS | CTRL, BACE1, PRSS1 | CYP2C9 470/4885ALDH1A1 4342/4885BLM 4552/4885 |
| US-20050282825-A1 | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase | BACE1, BACE2, APP | CYP2C9 3696/4885ALDH1A1 2182/4885BLM 4665/4885 |
| US-20060281730-A1 | Aspartyl protease inhibitors | CHRM1, CHRM2, BACE1 | CYP2C9 2053/4885ALDH1A1 3218/4885BLM 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.